Paratek Pharmaceuticals Inc (PRTK) was Initiated by Robert W. Baird to “Outperform” and the brokerage firm has set the Price Target at $30. Robert W. Baird advised their investors in a research report released on May 13, 2016.
Many Wall Street Analysts have commented on Paratek Pharmaceuticals Inc. Cantor Fitzgerald Resumed Paratek Pharmaceuticals Inc on Mar 30, 2016 to “Buy”, Price Target of the shares are set at $27.H.C. Wainwright Initiated Paratek Pharmaceuticals Inc on Feb 29, 2016 to “Buy”, Price Target of the shares are set at $32.
Paratek Pharmaceuticals Inc opened for trading at $12.79 and hit $13.0899 on the upside on Tuesday, eventually ending the session at $13.03, with a gain of 2.28% or 0.29 points. The heightened volatility saw the trading volume jump to 69,390 shares. Company has a market cap of $231 M.
In a different news, on Dec 14, 2015, Evan Loh (President and CMO) purchased 2,300 shares at $16.83 per share price.
Paratek Pharmaceuticals Inc. (Paratek) formerly Transcept Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s two antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). Sarecycline is in Phase III clinical trial stage for the treatment of acne and omadacycline has completed Phase III clinical trial for treatment of complicated skin and skin structure infection (cSSSI) and Phase II clinical trials for the treatment of ABSSSI and CABP. Sarecycline is a once-daily tetracycline-derived compound designed for use in the treatment of acne and rosacea.